Molecular biomarkers of risk in premalignancy and breast cancer prevention

Cancer Prevention Research

Volumn 4, Issue 12, 2011, Pages 1947-1952

  Allred, D Craig ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; AROMATASE; BIOLOGICAL MARKER; CLUSTER OF DIFFERENTIATION 24 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2; CYTOKERATIN 18; CYTOKERATIN 5; CYTOKERATIN 6; ESTROGEN RECEPTOR; HERMES ANTIGEN; PROTEIN; TAMOXIFEN; TUMOR MARKER; UNCLASSIFIED DRUG; VIMENTIN;

ACCURACY; ATYPICAL DUCTAL HYPERPLASIA; ATYPICAL LOBULAR HYPERPLASIA; BREAST BIOPSY; BREAST CANCER; BREAST HYPERPLASIA; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CANCER STEM CELL; CANCER TISSUE; CELL DIFFERENTIATION; CELL HYPERPLASIA; CELL MOTILITY; COLUMNAR CELL HYPERPLASIA; DIETARY INTAKE; DRUG EFFICACY; EXERCISE; GENE MUTATION; HIGH RISK POPULATION; HUMAN; INTRADUCTAL CARCINOMA; MALIGNANT TRANSFORMATION; MAMMOGRAPHY; NEEDLE BIOPSY; PARTIAL MASTECTOMY; PRECANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; UNITED STATES; WEIGHT REDUCTION;

BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; HUMANS; HYPERPLASIA; PRECANCEROUS CONDITIONS; TUMOR MARKERS, BIOLOGICAL;

EID: 83055162327     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0478     Document Type: Review

References (40)

1. Ghosh K, Melton LJ III, SumanVJ, Grant CS, Sterioff S, Brandt KR, et al. Breast biopsy utilization: a population-based study. Arch Intern Med 2005;165:1593-8. (Pubitemid 41124152)
2. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, et al. Benign breast disease and the risk of breast cancer. NEngl J Med 2005;353:229-37. (Pubitemid 41058322)
3. Page DL, Dupont WD. Anatomic indicators (histologic and cytologic) of increased breast cancer risk. Breast Cancer Res Treat 1993;28:157-66. (Pubitemid 24056087)
4. INK4a expression and BC risk in women with atypical hyperplasia. Cancer Prev Res 2011;4:1953-60.
5. Santisteban M, Reynolds C, Barr Fritcher EG, Frost MH, Vierkant RA, Anderson SS, et al. Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia. Breast Cancer Res Treat 2010;121:431-7.
6. Visscher DW, Pankratz VS, Santisteban M, Reynolds C, Ristimäki A, Vierkant RA, et al. Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst 2008;100:421-7. (Pubitemid 351480513)
7. Allred DC. Biomarkers predicting recurrence and progression of ductal carcinoma in situ treated by lumpectomy alone. J Natl Cancer Inst 2010;102:585-7.
8. Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 2010;102:627-37.
9. NIH. Search for Clinical Trails. Bethesda, MD: National Cancer Institute. [cited 2011]. Available from: http://www.cancer.gov/clinicaltrials/search.
10. Mahoney MC, Bevers T, Linos E, Willett WC. Opportunities and strategies for breast cancer prevention through risk reduction. CA Cancer J Clin 2008;58:347-71.
11. Blackburn EH, Tlsty TD, Lippman SM. Unprecedented opportunities and promise for cancer prevention research. Cancer Prev Res 2010;3:394-402.
12. Colditz GA. Epidemiology and prevention of breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:768-72. (Pubitemid 40478533)
13. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88. (Pubitemid 28439961)
14. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res 2010;3:696-706.
15. Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010;464:999-1005.
16. Sj€oblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74.
17. Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol 2010;28:3090-5.
18. Chen WY, Rosner B, Colditz GA. Moving forward with breast cancer prevention. Cancer 2007;109:2387-91. (Pubitemid 46906456)
19. Land SR, Cronin WM, Wickerham DL, Costantino JP, Christian NJ, Klein WM, et al. Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the national surgical adjuvant breast and bowel project p-1 breast cancer prevention trial. Cancer Prev Res 2011;4:1393-400.
20. William WN Jr, Heymach JV, Kim ES, Lippman SM. Molecular targets for cancer chemoprevention. Nat Rev Drug Discov 2009;8:213-25.
21. Rosen PP, Braun DW Jr, Kinne DE. The clinical significance of preinvasive breast carcinomas. Cancer 1980;46:919-25.
22. Page DL, Dupont WD, Rogers LW, Landenberger M. Intraductal carcinoma of the breast: follow-up after biopsy only. Cancer 1982;49:751-8. (Pubitemid 12165434)
23. Alpers CE, Wellings SR. The prevalence of carcinoma in situ in normal and cancer-associated breasts. Human Pathol 1985;16:796-807. (Pubitemid 15040815)
24. Wellings SR, Jensen HM, Marcum RG. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 1975;55:231-73.
25. Feeley L, Quinn CM. Columnar cell lesions of the breast. Histopathology 2008;52:11-9.
26. Lee S, Mohsin SK, Mao S, Hilsenbeck SG, Medina D, Allred DC. Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer. Breast Cancer Res 2006;8:R6.
27. Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res Treat 1998;48:221-9. (Pubitemid 28159950)
28. Wood CE, Usborne AL, Starost MF, Tarara RP, Hill LR, Wilkinson LM, et al. Hyperplastic and neoplastic lesions of the mammary gland in macaques. Vet Pathol 2006;43:471-83. (Pubitemid 44065861)
29. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res 2011;4:1021-9.
30. Lee S, Medina D, Tsimelzon A, Mohsin SK, Mao S, Wu Y, et al. Alterations of gene expression in the development of early hyperplastic precursors of breast cancer. Am J Pathol 2007;171:252-62. (Pubitemid 47339242)
31. Allred DC, Wu Y, Mao S, Nagtegaal ID, Lee S, Perou CM, et al. Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 2008;14:370-8. (Pubitemid 351226103)
32. O'Connell P, Pekkel V, Fuqua SAW, Osborne CK, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 1998;90:697-703. (Pubitemid 28222144)
33. Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, et al. Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res 2003;1:362-75. (Pubitemid 36437922)
34. Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, Walter M, et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 2006;66:5278-86. (Pubitemid 43844952)
35. Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 2003;100:5974-9. (Pubitemid 36576916)
36. Behbod F, Kittrell FS, LaMarca H, Edwards D, Kerbawy S, Heestand JC, et al. An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res 2009;11:R66.
37. Park SY, Gonen M, Kim HJ, Michor F, Polyak K. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest 2010;120:636-44.
38. Crawford YG, Gauthier ML, Joubel A, Mantei K, Kozakiewicz K, Afshari CA, et al. Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program. Cancer Cell 2004;5:263-73. (Pubitemid 38402118)
39. Holst CR, Nuovo GJ, Esteller M, Chew K, Baylin SB, Herman JG, et al. Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res 2003;63:1596-601. (Pubitemid 36373649)
40. McDermott KM, Zhang J, Holst CR, Kozakiewicz BK, Singla V, Tlsty TD. p16(INK4a) prevents centrosome dysfunction and genomic instability in primary cells. PLoS Biol 2006;4:e51.